What Dicetel Treats

Dicetel, which contains the active ingredient pinaverium bromide, is a medication primarily used to manage symptoms associated with functional gastrointestinal disorders. It belongs to a class of drugs known as antispasmodics and acts as a selective calcium channel blocker for the smooth muscles of the digestive tract.

Main Uses

The medication is most commonly prescribed for the following conditions:

• Irritable Bowel Syndrome (IBS): Dicetel is used to treat the symptoms of IBS, a chronic condition affecting the large intestine.
• Biliary Tract Disorders: It may be used to address functional symptoms related to the bile ducts.
• Gastrointestinal Motility Disorders: The drug helps manage various functional disturbances of the intestinal transit.

Benefits and Symptom Relief

Dicetel works by relaxing the smooth muscles of the bowel and gastrointestinal tract. By reducing the hypersensitivity and excessive contractions of these muscles, it helps alleviate several common symptoms:

• Abdominal Pain and Cramping: By preventing muscle spasms, it can reduce the frequency and intensity of abdominal discomfort.
• Bloating and Distension: The medication helps normalize bowel movements, which may reduce the feeling of fullness or visible swelling in the abdomen.
• Altered Bowel Habits: It can assist in managing the irregular bowel patterns (such as diarrhea or constipation) often associated with irritable bowel syndrome.

Unlike some other treatments that may affect the cardiovascular system, the action of Dicetel is largely localized to the gastrointestinal tract, focusing its benefits on the digestive system.

Who Can and Cannot Use Dicetel? (Pinaverium Bromide)

This section summarizes the officially documented rules regarding who is eligible to use Dicetel, based strictly on government regulatory product information.

Dicetel is generally positioned for use in adult populations (18 years and older).

---

Absolute Non-Eligibility (Contraindications)

Individuals must not use Dicetel if they have:

• A known allergy or hypersensitivity to the active ingredient, Pinaverium Bromide, or to any of the other tablet components (excipients).
• Certain rare hereditary metabolic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, due to the presence of lactose in the tablet.

---

Population Restrictions

Population	Official Eligibility Status
Children and Adolescents (under 18)	Not recommended; safety and efficacy are not established.
Pregnant Women	Not recommended; use only if judged essential by a physician.
Breastfeeding Women	Not recommended; risk to the nursing infant cannot be excluded.

---

Conditional Use

Use requires caution in patients with pre-existing esophageal lesions (like esophagitis or hiatal hernia) or poor esophageal motility. This restriction is noted due to the risk of local irritation from the oral tablet form.

The regulatory profile for Dicetel (pinaverium bromide) is largely defined by its limited systemic absorption, which correlates with a low potential for clinically significant pharmacokinetic interaction.

Interaction Scope	Official Regulatory Statements
Pharmacodynamic Potential	Co-administration with an anticholinergic drug may result in a pharmacodynamic interaction that enhances spasmolysis (additive effect).
Systemic Exposure	Clinical trials confirmed the absence of any interaction with major systemic medications, including digitalis drugs, oral anti-diabetics, insulin, and oral anticoagulants (e.g., acenocoumarol).
Timing/Food Restriction	The tablet must be taken with food and swallowed with a full glass of water. This requirement is a mandatory restriction designed to prevent the local risk of esophageal lesion.

The interaction profile confirms that no substances are officially classified as contraindicated due to metabolic or transporter effects. The primary risks documented by regulatory authorities involve the potential for an additive pharmacodynamic effect with anticholinergic agents and the critical administration timing constraint necessary to ensure the local safety of the esophageal mucosa. This structure ensures focus remains strictly on label-based interaction information.

Selective Blockade of Gastrointestinal Calcium Channels

Dicetel (pinaverium bromide) functions as a selective antagonist of voltage-dependent L-type calcium channels (alpha1S subunit) located on the smooth muscle cells of the gastrointestinal (GI) tract. The drug binds to the channel, inhibiting the inward flux of extracellular calcium ions ( Ca^2+) into the cell. This specific interaction defines the initial step of the drug's mechanism.

---

Direct Modulation of Smooth Muscle Contraction

Modulation of the calcium ion influx directly affects the excitation-contraction coupling pathway in the muscle cells. This action leads to the relaxation of the intestinal smooth muscle, which directly decreases the strength and frequency of abnormal contractions. This mechanistic cascade results in the physiological consequence of reduced gastrointestinal motility and tone.

---

Peripheral and Highly Targeted Action

Dicetel's effect is confined primarily to the digestive tract (peripheral action). Its poor absorption into the systemic circulation ensures the mechanism is spatially restricted and highly targeted to the GI system. This high level of selectivity means the mechanistic action is primarily confined to the gut wall, with limited functional impact on cardiovascular system calcium channels.

Administration Guidelines for Dicetel (Pinaverium Bromide)

The usage of Dicetel is defined by specific protocols regarding the route, dose, and administration context. The active ingredient, pinaverium bromide, is supplied as a film-coated tablet for oral administration.

Dosing and Scheduling

The standard adult dosage is typically 50 mg three times a day. This may be increased to a maximum of 100 mg three times a day, resulting in a maximum total daily dose of 300 mg. The duration of treatment depends on the condition being addressed. For use as a preparation for a barium enema, the regimen is 2 tablets twice a day for the 3 days preceding the procedure.

Procedural Administration Rules

Specific methods of intake are required to avoid localized irritation. Tablets must be taken during the middle of a meal or snack and swallowed whole with a full glass of water. The tablet must not be chewed, crushed, or sucked.

Furthermore, the medication should not be swallowed while in a lying position, and the patient should not lie down immediately after taking the dose. If a dose is missed, the missed dose should be skipped and the next scheduled dose taken at the usual time; a double dose should not be taken. Dicetel is not recommended for use in children due to limited safety and efficacy data regarding the pediatric population.

Research evidence / Overview of Studies for Dicetel (Pinaverium Bromide)

Evidence for Use in Irritable Bowel Syndrome (IBS)

Research exploring pinaverium bromide in the setting of Irritable Bowel Syndrome has primarily relied on Randomized Controlled Trials (RCTs). These short-term studies, many of which were placebo-controlled, were used in research exploring how symptoms change over time in adult patients diagnosed with IBS. The findings from these individual trials have been combined and assessed in multiple comprehensive systematic reviews and meta-analyses.

In these studies, researchers examined outcomes related to physical discomfort, most frequently tracking patient-reported outcomes describing perceived discomfort of IBS symptoms as a primary endpoint. Pooled analyses of the available RCT data findings indicate patterns where observed outcomes reflecting perceived discomfort were reported more frequently in the observed study arms receiving pinaverium bromide when compared to placebo arms. The main evidence is characterized by follow-up durations that were often limited to short-term observation periods, commonly spanning 2 to 4 weeks.

Evidence for Functional Biliary Tract Disorders

Pinaverium bromide was studied for conditions characterized by functional limitations involving the bile ducts and gallbladder. The evidence in this area includes clinical trials that used specialized monitoring. In this research, studies focused on episodes where symptoms become more noticeable, such as reported outcomes describing episodic or acute changes like measurements of epigastric pain. Findings from trials described patterns in physiological measurements when compared to control groups.

Consolidated evidence from recent, large-scale systematic reviews is less available for this indication compared to the data available for IBS. Furthermore, the findings are sometimes challenging to generalize due to the complexity and diagnostic overlap between functional biliary disorders and other types of functional gastrointestinal conditions.

What is Still Uncertain About the Evidence

Despite the body of research, certainty remains low in several areas related to pinaverium bromide. Research highlights that studies conducted to date provide limited information for long-term outcomes and maintenance therapy. Comparative evidence is limited; studies primarily focused on comparison against a placebo. Additionally, the broad scientific evidence base indicates that the observed patterns may vary across patient subgroups.

Key Studies & References

1. Pinaverium Reduces Symptoms of Irritable Bowel Syndrome in a Multicenter, Randomized, Controlled Trial
2. Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines (CADTH Rapid Response Report)

Dicetel film-coated tablets must be stored according to specific regulatory conditions to maintain their stability.

Storage Requirements

The medication must be stored at room temperature, typically defined by regulatory agencies as 15 C to 30 C or 15 C to 25 C. To protect the tablets, they must be stored in a location that provides protection from light and moisture. Tablets should be kept in their original packaging until the expiry date. A mandatory requirement is that Dicetel be stored securely and out of the reach of children.

Disposal Instructions

Official labeling directs that unused or expired Dicetel must not be disposed of in wastewater (e.g., flushed down the toilet or sink) or placed in household garbage. The preferred and safest method for disposal is to utilize a drug take-back program or to ask a pharmacist for guidance on safe and environmentally compliant pharmaceutical waste channels.